Co-Diagnostics (CODX) Competitors

$1.28 -0.35 (-21.17%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$1.28 0.00 (0.00%)

As of 05/15/2026 07:53 PM Eastern

CODX vs. FEMY, POAI, OSRH, RVP, and ICCM

Should you buy Co-Diagnostics stock or one of its competitors? MarketBeat compares Co-Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Co-Diagnostics include Femasys (FEMY), Predictive Oncology (POAI), OSR (OSRH), Retractable Technologies (RVP), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry.

How does Co-Diagnostics compare to Femasys?

Co-Diagnostics (NASDAQ:CODX) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 5,152.92%. Femasys has a consensus target price of $5.33, indicating a potential upside of 1,395.61%. Given Co-Diagnostics' higher probable upside, research analysts clearly believe Co-Diagnostics is more favorable than Femasys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Co-Diagnostics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Femasys has a beta of -2.26, suggesting that its share price is 326% less volatile than the broader market.

Femasys has a net margin of -521.97% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -143.23% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-143.23%	-125.49%
Femasys	-521.97%	-258.08%	-73.72%

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 7.6% of Femasys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Co-Diagnostics had 6 more articles in the media than Femasys. MarketBeat recorded 9 mentions for Co-Diagnostics and 3 mentions for Femasys. Femasys' average media sentiment score of 0.98 beat Co-Diagnostics' score of -0.24 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Femasys has higher revenue and earnings than Co-Diagnostics. Femasys is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	7.46	-$46.90M	-$29.73	N/A
Femasys	$2.38M	9.06	-$18.63M	-$0.27	N/A

Summary

Femasys beats Co-Diagnostics on 11 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to Predictive Oncology?

Co-Diagnostics (NASDAQ:CODX) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Predictive Oncology has higher revenue and earnings than Co-Diagnostics. Predictive Oncology is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	7.46	-$46.90M	-$29.73	N/A
Predictive Oncology	$1.66M	11.93	-$12.66M	-$13.50	N/A

Co-Diagnostics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 5,152.92%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, research analysts clearly believe Co-Diagnostics is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has a net margin of -5,065.23% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -143.23% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-143.23%	-125.49%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

In the previous week, Co-Diagnostics had 8 more articles in the media than Predictive Oncology. MarketBeat recorded 9 mentions for Co-Diagnostics and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.75 beat Co-Diagnostics' score of -0.24 indicating that Predictive Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Predictive Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Co-Diagnostics beats Predictive Oncology on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to OSR?

Co-Diagnostics (NASDAQ:CODX) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

OSR has higher revenue and earnings than Co-Diagnostics. OSR is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	7.46	-$46.90M	-$29.73	N/A
OSR	$2.91M	6.89	-$27.06M	-$0.33	N/A

Co-Diagnostics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, OSR has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 5,152.92%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities analysts plainly believe Co-Diagnostics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OSR has a net margin of -363.26% compared to Co-Diagnostics' net margin of -6,760.63%. OSR's return on equity of -7.24% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-143.23%	-125.49%
OSR	-363.26%	-7.24%	-5.41%

In the previous week, Co-Diagnostics had 5 more articles in the media than OSR. MarketBeat recorded 9 mentions for Co-Diagnostics and 4 mentions for OSR. OSR's average media sentiment score of 0.23 beat Co-Diagnostics' score of -0.24 indicating that OSR is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OSR	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 60.6% of OSR shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

OSR beats Co-Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to Retractable Technologies?

Co-Diagnostics (NASDAQ:CODX) and Retractable Technologies (NYSE:RVP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

In the previous week, Co-Diagnostics had 6 more articles in the media than Retractable Technologies. MarketBeat recorded 9 mentions for Co-Diagnostics and 3 mentions for Retractable Technologies. Retractable Technologies' average media sentiment score of 0.00 beat Co-Diagnostics' score of -0.24 indicating that Retractable Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Retractable Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 59.5% of Retractable Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Retractable Technologies has higher revenue and earnings than Co-Diagnostics. Retractable Technologies is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	7.46	-$46.90M	-$29.73	N/A
Retractable Technologies	$38.27M	0.50	-$7.01M	-$0.42	N/A

Co-Diagnostics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Retractable Technologies has a net margin of -41.11% compared to Co-Diagnostics' net margin of -6,760.63%. Retractable Technologies' return on equity of -17.15% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-143.23%	-125.49%
Retractable Technologies	-41.11%	-17.15%	-9.33%

Summary

Co-Diagnostics and Retractable Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to IceCure Medical?

Co-Diagnostics (NASDAQ:CODX) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

In the previous week, IceCure Medical had 9 more articles in the media than Co-Diagnostics. MarketBeat recorded 18 mentions for IceCure Medical and 9 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of -0.24 beat IceCure Medical's score of -0.31 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IceCure Medical	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IceCure Medical has higher revenue and earnings than Co-Diagnostics. IceCure Medical is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	7.46	-$46.90M	-$29.73	N/A
IceCure Medical	$3.38M	5.52	-$15.06M	-$0.24	N/A

Co-Diagnostics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Co-Diagnostics currently has a consensus price target of $67.50, indicating a potential upside of 5,152.92%. IceCure Medical has a consensus price target of $2.09, indicating a potential upside of 809.49%. Given Co-Diagnostics' higher possible upside, research analysts plainly believe Co-Diagnostics is more favorable than IceCure Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

IceCure Medical has a net margin of -441.60% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -143.23% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-143.23%	-125.49%
IceCure Medical	-441.60%	-211.73%	-119.13%

Summary

Co-Diagnostics and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.87M	$8.29B	$6.43B	$12.48B
Dividend Yield	N/A	3.05%	2.80%	5.25%
P/E Ratio	-0.04	21.86	20.38	25.24
Price / Sales	7.46	20.67	566.19	82.25
Price / Cash	N/A	80.56	43.04	56.04
Price / Book	0.14	5.45	9.87	6.90
Net Income	-$46.90M	$183.43M	$3.57B	$334.66M
7 Day Performance	-49.21%	-1.16%	0.31%	0.13%
1 Month Performance	-11.99%	0.47%	-1.27%	1.11%
1 Year Performance	-85.72%	-0.37%	33.54%	30.62%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	1.7163 of 5 stars	$1.29 -21.2%	$67.50 +5,152.9%	-86.0%	$5.87M	$620K	N/A	100	News Coverage Earnings Report Short Interest Increase Gap Down
FEMY Femasys	2.9075 of 5 stars	$0.38 -6.7%	$5.50 +1,358.5%	-66.7%	$22.77M	$2.29M	N/A	30	Earnings Report
POAI Predictive Oncology	0.1739 of 5 stars	$6.66 +17.5%	N/A	-66.1%	$22.60M	$1.66M	N/A	30	News Coverage
OSRH OSR	0.7159 of 5 stars	$0.64 +13.1%	N/A	-50.0%	$21.27M	$2.91M	N/A	N/A	Earnings Report Short Interest Increase
RVP Retractable Technologies	N/A	$0.70 +2.4%	N/A	-14.7%	$20.96M	$38.27M	N/A	240	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. FEMY, POAI, OSRH, RVP, and ICCM

How does Co-Diagnostics compare to Femasys?

Summary

How does Co-Diagnostics compare to Predictive Oncology?

Summary

How does Co-Diagnostics compare to OSR?

Summary

How does Co-Diagnostics compare to Retractable Technologies?

Summary

How does Co-Diagnostics compare to IceCure Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. FEMY, POAI, OSRH, RVP, and ICCM

How does Co-Diagnostics compare to Femasys?

Do analysts recommend CODX or FEMY?

Which has more volatility & risk, CODX or FEMY?

Is CODX or FEMY more profitable?

Do institutionals and insiders believe in CODX or FEMY?

Does the media refer more to CODX or FEMY?

Which has higher earnings and valuation, CODX or FEMY?

Summary

How does Co-Diagnostics compare to Predictive Oncology?

Which has higher earnings and valuation, CODX or POAI?

Which has more volatility & risk, CODX or POAI?

Do analysts recommend CODX or POAI?

Is CODX or POAI more profitable?

Does the media refer more to CODX or POAI?

Do institutionals and insiders believe in CODX or POAI?

Summary

How does Co-Diagnostics compare to OSR?

Which has stronger earnings & valuation, CODX or OSRH?

Which has more risk & volatility, CODX or OSRH?

Do analysts recommend CODX or OSRH?

Is CODX or OSRH more profitable?

Does the media refer more to CODX or OSRH?

Do insiders & institutionals believe in CODX or OSRH?

Summary

How does Co-Diagnostics compare to Retractable Technologies?

Does the media refer more to CODX or RVP?

Do insiders & institutionals believe in CODX or RVP?

Which has stronger earnings & valuation, CODX or RVP?

Which has more risk & volatility, CODX or RVP?

Do analysts recommend CODX or RVP?

Is CODX or RVP more profitable?

Summary

How does Co-Diagnostics compare to IceCure Medical?

Does the media prefer CODX or ICCM?

Do institutionals & insiders believe in CODX or ICCM?

Which has higher earnings and valuation, CODX or ICCM?

Which has more risk and volatility, CODX or ICCM?

Do analysts recommend CODX or ICCM?

Is CODX or ICCM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools